Cardiff Oncology, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.17 | $-0.14 | +17.6% | Beat |
| Q12026 FY2026 | $-0.13 | $-0.18 | -38.5% | Miss |
| Q42025 FY2025 | $-0.18 | $-0.11 | +38.9% | Beat |
Back to CRDF overview · CRDF holders · CRDF KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.